6-溴-5-甲基咪唑并[1,2-A]吡啶-2-羧酸乙酯 | 859787-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-溴-5-甲基咪唑并[1,2-A]吡啶-2-羧酸乙酯
• 中文别名: 6-溴-5-甲基h-咪唑并[1,2-a]吡啶-2-羧酸乙酯
• 英文名称: ethyl 6-bromo-5-methylimidazo[1,2-a]pyridine-2-carboxylate
• 英文别名: 6-bromo-5-methyl-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester
• CAS: 859787-40-9
• 化学式: C₁₁H₁₁BrN₂O₂
• 分子量: 283.125
• InChiKey: BDQNBVZMHDJQBT-UHFFFAOYSA-N

物化性质

• 密度：
  1.54±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-溴-5-甲基咪唑并[1,2-A]吡啶-2-羧酸乙酯 在 palladium on activated charcoal 吡啶 、 4-二甲氨基吡啶 、 ammonium hydroxide 、 硫酸 、 potassium tert-butylate 、 氢气 、 硝酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 2.0h， 生成 6-Bromo-3-(2-ethoxy-phenyl)-5-methyl-2H-2,4,4b,9-tetraaza-fluoren-1-one
  参考文献：
  名称：

  Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives

  摘要：

  Synthesis and primary SAR of a novel series of 2-phenylpyrido[1,2-e]purin-4(3H)-one derivatives with piperazinyl sulfonamide substituents were described herein. As potential PDE5 inhibitors for erectile dysfunction (ED) treatment, representative compounds exhibit improved selectivity versus PDE1 and PDE6. Meanwhile, compound 3e demonstrated functional efficacy on rabbit corpus cavernosum strip in vitro. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.102
• 作为产物：
  描述：

  2-氨基-5-溴-6-甲基吡啶 、 3-溴丙酮酸乙酯 以 乙醇 为溶剂， 反应 3.0h， 生成 6-溴-5-甲基咪唑并[1,2-A]吡啶-2-羧酸乙酯
  参考文献：
  名称：

  [EN] SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS ß-SECRETASE INHIBITORS
  [FR] DÉRIVÉS IMIDAZO[1,2-A]PYRIDINE SUBSTITUÉS, COMPOSITIONS PHARMACEUTIQUES, ET PROCÉDÉS D'UTILISATION COMME INHIBITEURS DE LA ?-SÉCRÉTASE

  摘要：

  本发明涉及替代咪唑[1,2-a]吡啶衍生物，其药学上可接受的盐，以及这些化合物或盐的互变异构体，其抑制β-淀粉样前体蛋白裂解酶（BACE）并且可能在治疗涉及BACE的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物以及在治疗涉及BACE的这类疾病中使用这些化合物和组合物。

  公开号：

  WO2010126745A1

文献信息

• 2-BENZOYLIMIDAZOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：PEYRONEL Jean-Francois

  公开号：US20090143420A1

  公开（公告）日：2009-06-04

  The present invention is related to a compound of formula (I) wherein R1, R2, R3, R4 and X are as defined herein, or an acid-addition salt thereof, its preparation and therapeutic use in the treatment or prevention of diseases involving the Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.

  本发明涉及一种化合物，其化学式为(I)，其中R1、R2、R3、R4和X如本文所定义，或其酸盐，以及其制备和在治疗或预防涉及Nurr-1核受体（也称为NR4A2、NOT、TINUR、RNR-1和HZF3）相关疾病中的治疗用途。
• [EN] SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS ß-SECRETASE INHIBITORS<br/>[FR] DÉRIVÉS IMIDAZO[1,2-A]PYRIDINE SUBSTITUÉS, COMPOSITIONS PHARMACEUTIQUES, ET PROCÉDÉS D'UTILISATION COMME INHIBITEURS DE LA ?-SÉCRÉTASE
  申请人：HIGH POINT PHARMACEUTICALS LLC

  公开号：WO2010126745A1

  公开（公告）日：2010-11-04

  The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.

  本发明涉及替代咪唑[1,2-a]吡啶衍生物，其药学上可接受的盐，以及这些化合物或盐的互变异构体，其抑制β-淀粉样前体蛋白裂解酶（BACE）并且可能在治疗涉及BACE的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物以及在治疗涉及BACE的这类疾病中使用这些化合物和组合物。
• 2-benzoylimidazopyridine derivatives, preparation and therapeutic use thereof
  申请人：Sanofi-Aventis

  公开号：US07902219B2

  公开（公告）日：2011-03-08

  The present invention is related to a compound of formula (I) wherein R1, R2, R3, R4 and X are as defined herein, or an acid-addition salt thereof, its preparation and therapeutic use in the treatment or prevention of diseases involving the Nurr-1 nuclear receptors, also known as NR4A2, NOT, TINUR, RNR-1 and HZF3.

  本发明涉及一种式（I）的化合物，其中R1，R2，R3，R4和X如本文所定义，或其酸加成盐，其制备和在治疗或预防涉及Nurr-1核受体（也称为NR4A2，NOT，TINUR，RNR-1和HZF3）的疾病中的治疗用途。
• SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
  申请人：Mjalli Adnan M. M.

  公开号：US20120101093A1

  公开（公告）日：2012-04-26

  The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.

  本发明涉及取代的咪唑并[1,2-a]吡啶衍生物、其药学上可接受的盐以及这些化合物或盐的互变异构体，其抑制β-淀粉样前体蛋白裂解酶（BACE），并且可能在治疗BACE参与的疾病，如阿尔茨海默病中有用。本发明还涉及包含这些化合物的制药组合物和使用这些化合物和组合物治疗BACE参与的这些疾病的方法。
• AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1849465A1

  公开（公告）日：2007-10-31

  The present invention provides a GPR receptor function regulator comprising the compound represented by the formula: [wherein ring A is an optionally substituted isocyclic or heterocyclic ring, P is a bond or spacer, ring D is an optionally substituted monocyclic aromatic ring which may be condensed with a 5-to 7-membered ring, V is a bond or the group represented by the formula -CR14=CR15 - or - N=CR16- (wherein R14, R15 and R16 each represents a hydrogen atom or optionally substituted hydrocarbon group), Q is a bond or spacer, and W is a carboxyl or a group biologically equivalent to a carboxyl] or its salt or a prodrug thereof

  本发明提供了一种 GPR 受体功能调节剂，包括由式表示的化合物： [其中环A是任选取代的异环或杂环，P是键或间隔物，环D是任选取代的单环芳香环，可与5-7元环缩合，V是键或由式-CR14＝CR15-或-N＝CR16-代表的基团（其中R14、R15 和 R16 各代表一个氢原子或任选取代的烃基），Q 是键或间隔物，W 是羧基或生物等价于羧基的基团]或其盐或其原药